MIVI Neuroscience

Executive Summary

MIVI Neuroscience is a privately held medical device company headquartered in Eden Prairie, Minnesota, with a singular mission to expand the boundaries of stroke treatment. Founded in 2015, the company is dedicated to equipping physicians with advanced tools that improve patient outcomes, particularly in the most challenging cases. While specific product details and financial data are not publicly disclosed, the company's focus on neurovascular intervention places it in a high-growth market driven by aging populations and increasing stroke incidence. MIVI's technology aims to address unmet needs in thrombectomy and other acute ischemic stroke therapies, where procedural complexity and variable anatomy often limit success rates. The company's private status and lack of disclosed funding rounds suggest it may be in earlier stages of commercialization or relying on internal resources. However, the neurovascular device space has seen significant M&A and partnership activity, offering potential exit opportunities. MIVI's success will hinge on obtaining regulatory clearances, generating compelling clinical evidence, and establishing commercial partnerships. The stroke treatment market is projected to grow steadily, and innovative devices that can safely and effectively remove clots in difficult vessels could capture meaningful share. While the absence of public milestones adds uncertainty, MIVI's focused mission and niche address a critical healthcare need.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation thrombectomy device70% success
• Q4 2026Publication of pivotal clinical data from a multicenter trial60% success
• Q2 2027Strategic partnership or distribution agreement with a major neurovascular company50% success